We are live on
!
Find out more
TLP
Tri Locum Partners Portfolio holdings
AUM
$713M
1-Year Est. Return
68.92%
This Fund
S&P 500
This Quarter
Est. Return
-5.96%
1 Year Est. Return
+68.92%
3 Year Est. Return
+377.81%
5 Year Est. Return
+1,289.15%
10 Year Est. Return
–
AUM
$256M
AUM Growth
+$1.99M
(+0.78%)
Cap. Flow
+$21M
Cap. Flow
% of AUM
8.19%
Top 10 Holdings %
Top 10 Hldgs %
54.27%
Holding
61
New
20
Increased
9
Reduced
8
Closed
24
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Jazz Pharmaceuticals
JAZZ
|
+$19M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$13.6M |
| 3 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$12.9M |
| 4 |
Protagonist Therapeutics
PTGX
|
+$12.8M |
| 5 |
Celldex Therapeutics
CLDX
|
+$12.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$24.4M |
| 2 |
APLS
Apellis Pharmaceuticals
APLS
|
+$15M |
| 3 |
United Therapeutics
UTHR
|
+$9.92M |
| 4 |
Eli Lilly
LLY
|
+$9.5M |
| 5 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$9.27M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.85% |
| 2 | Consumer Staples | 3.25% |
| 3 | Financials | 0.9% |
| 4 | Real Estate | 0.04% |
| 5 | Technology | 0.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Xenon Pharmaceuticals
XENE
$6.11B
| – | – |
-25,043
| Closed | -$782K |
|
52
Zentalis Pharmaceuticals
ZNTL
$297M
| – | – |
-23,632
| Closed | -$1.99M |
|
|
ITCI
53
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| – | – |
-26,177
| Closed | -$1.37M |
|
|
CTLT
54
DELISTED
CATALENT, INC.
CTLT
| – | – |
-23,700
| Closed | -$3.03M |
|
|
AWH
55
DELISTED
Aspira Women's Health Inc. Common Stock
AWH
| – | – |
-725
| Closed | -$19K |
|
|
SNCE
56
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
| – | – |
-13,558
| Closed | -$3.38M |
|
|
SGEN
57
DELISTED
Seagen Inc. Common Stock
SGEN
| – | – |
-59,940
| Closed | -$9.27M |
|
|
CANO
58
DELISTED
Cano Health, Inc.
CANO
| – | – |
-1,415
| Closed | -$1.26M |
|
|
ONEM
59
DELISTED
1Life Healthcare
ONEM
| – | – |
-84,748
| Closed | -$1.49M |
|
|
ABMD
60
DELISTED
Abiomed Inc
ABMD
| – | – |
-5,169
| Closed | -$1.86M |
|
|
ATHX
61
DELISTED
Athersys, Inc. Common Stock
ATHX
| – | – |
-778
| Closed | -$18K |
|
Similar funds
DCM
AMPWP
DCM
ACGDR
GEA
ECM
SSP
DIA
Tri Locum Partners's Q1 2022 Portfolio in Review
As of Q1 2022, Tri Locum Partners held 61 positions worth $256M, up 0.78% from $254M the previous quarter. Its ten largest holdings account for 54% of the portfolio.
Tri Locum Partners deployed $21M of net new capital in Q1 2022, opening 20 new positions and adding to 9 existing holdings. Its largest new stake was Jazz Pharmaceuticals: 130,678 shares worth $20.3M.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 87% a quarter earlier, followed by Consumer Staples and Financials.
On the sell side, the largest reduction was Eli Lilly, an estimated $9.5M trimmed.
- Tri Locum Partners's largest Q1 2022 buy was Jazz Pharmaceuticals: 130,678 shares worth $20.3M.
- Tri Locum Partners added most to Protagonist Therapeutics in Q1 2022, an estimated $12.8M increase.
- Tri Locum Partners's biggest Q1 2022 reduction was Eli Lilly, cutting an estimated $9.5M.
- Tri Locum Partners fully exited AbbVie in Q1 2022, selling an estimated $24.4M.
- Tri Locum Partners's ten largest holdings make up 54% of its $256M portfolio in Q1 2022.
- Tri Locum Partners opened 20 new positions and closed 24 in Q1 2022.
- Tri Locum Partners's portfolio value rose 0.78% quarter-over-quarter to $256M.
Based on Tri Locum Partners's 13F filing for Q1 2022, filed 16 May 2022.